<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Identifying and managing casualties of biological terrorism</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Identifying and managing casualties of biological terrorism</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Identifying and managing casualties of biological terrorism</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amesh A Adalja, MD, FACP, FACEP, FIDSA</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Sexton, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard D Zane, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 10, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H16715219"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Terrorism can come in many forms. Biological events have the potential to be more readily disseminated and destructive than chemical or nuclear weapons [<a href="#rid1">1</a>]. The United States Congressional Office of Technology Assessment has estimated that a 100 kg payload of aerosolized anthrax spores, if released upwind of Washington, DC, could result in 130,000 to 3 million deaths, matching the lethality of the hydrogen bomb [<a href="#rid2">2</a>]. Lethal amounts of biological agents are relatively easy to manufacture, conceal, transport, and release. However, there is a growing consensus that manufacture of biological agents requires some amount of tacit knowledge, thus limiting the scope of individuals who have the capacity to initiate a large-scale attack [<a href="#rid3">3</a>].</p><p>As with emerging infectious diseases, detection and control of biological attacks depend upon a strong and flexible public health system at the local, state and federal levels. Additionally, well-trained and vigilant front line health professionals are required, especially in detecting covert biological attacks. Primary health care providers will likely be the first to observe and report any unusual illness patterns in the event of such an attack.</p><p>This topic will address the history of bioterrorism, the organisms of greatest concern, and the immediate management of persons with possible exposure. </p><p>Treatment of established infections, such as anthrax, is discussed in the topics dedicated to those pathogens.</p><p>Chemical terrorism is discussed separately. (See  <a class="medical medical_review" href="/d/html/2020.html" rel="external">"Chemical terrorism: Rapid recognition and initial medical management"</a>.)</p><p class="headingAnchor" id="H16715226"><span class="h1">HISTORICAL PERSPECTIVE</span><span class="headingEndMark"> — </span>The greatest advancements in biological weapons occurred in the twentieth century. Attacks have been targeted at both animals and humans [<a href="#rid4">4</a>], and have been perpetrated by multiple nations.</p><p>The first attempts at restricting the proliferation of biological capacity occurred with the 1925 Geneva Protocol for the "Prohibition of the Use in War of Asphyxiating, Poisonous or Other Gases, and of Biological Methods of Warfare" [<a href="#rid1">1</a>]. However, even after ratification, most countries continued to develop their biologic capacity. The United States built an offensive weapons program at Camp Detrick in 1942 and continued to develop technology in this area, fueled by the ensuing Cold War [<a href="#rid5">5</a>]. President Richard Nixon ended this offensive program in 1969. A multilateral treaty, known as the Biological Weapons Convention (BWC), was developed in 1972, and has been signed by 175 countries. </p><p>However, there had subsequently been evidence of ongoing use of biologic weapons in other countries, such as Iraq and the former Soviet Union [<a href="#rid6">6,7</a>]. The accidental release of aerosolized anthrax spores from a Soviet weapons plant in Sverdlovsk resulted in the deaths of at least 68 people from inhalation anthrax [<a href="#rid8">8</a>]. </p><p class="headingAnchor" id="H16715233"><span class="h2">Evidence of prior bioterrorism</span><span class="headingEndMark"> — </span>Terrorist groups and religious cults have also employed biological agents worldwide. </p><p class="headingAnchor" id="H1211773"><span class="h3">United States</span><span class="headingEndMark"> — </span>In the United States, there have been several instances of biologic terrorism over the past few decades including the following events: </p><p class="bulletIndent1"><span class="glyph">●</span>In 1984, a religious cult intentionally infected restaurant salad bars in Oregon with salmonella, resulting in disease amongst 751 people; this episode revealed the vulnerability of the food and water supply [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/2683.html" rel="external">"Nontyphoidal Salmonella: Microbiology and epidemiology"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 2001, 22 people in the United States developed inhalational or cutaneous anthrax when this biological agent was sent through the mail to multiple states, resulting in five deaths [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/5533.html" rel="external">"Clinical manifestations and diagnosis of anthrax"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 2003, an envelope with a threatening note and a sealed container containing ricin was processed at a mail processing and distribution facility in South Carolina [<a href="#rid11">11</a>]. An investigation by the Centers for Disease Control and Prevention (CDC) found no evidence of environmental contamination and no cases of ricin-associated illness. Ricin has been employed in multiple similar episodes, which include letters to President Barack Obama, a United States senator, and a Mississippi judge [<a href="#rid12">12</a>]. </p><p></p><p>The United States also has a number of BioSafety Level (BSL) 3 and 4 laboratories spread across the country. A hurricane, or similar natural disaster, if located near such a facility, could theoretically result in an accidental release of organisms [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H1211780"><span class="h3">Worldwide</span><span class="headingEndMark"> — </span>The Japanese cult, Aum Shinrykio, used sarin nerve gas for its attack on the Tokyo subway resulting in over 6000 casualties and 12 deaths in 1995 [<a href="#rid14">14</a>]. The group also attempted to disperse anthrax and botulism on at least eight occasions; these attacks were associated with no known illness. Other groups who have reportedly used biological weapons include the Viet Cong, who used focally contaminated spears during the Vietnam War, and the Mau rebels in Kenya, who used plant latex toxins to kill cattle [<a href="#rid15">15</a>]. </p><p class="headingAnchor" id="H20472916"><span class="h1">THE ROLE OF REGULATORY AGENCIES</span><span class="headingEndMark"> — </span>The United States Centers for Disease Control and Prevention (CDC) has been designated by the United States Department of Health and Human Services to coordinate and lead the planning efforts to upgrade national public health capabilities at the local, state, and federal level. Liaison channels now also exist between the CDC, the Federal Bureau of Investigation (FBI), and Federal Emergency Management Agency (FEMA) in order to better coordinate responses of national relevance. The FBI has jurisdiction over a bioterrorism response. </p><p class="headingAnchor" id="H1212247"><span class="h1">OVERVIEW OF DETECTION AND RESPONSE</span><span class="headingEndMark"> — </span>Detection of biological agents can be difficult since biological events are frequently invisible and lead to slow accumulation of casualties, in contrast to chemical spills, which often lead to rapid casualties. The appropriate responses to a potential bioterrorism event include: </p><p class="bulletIndent1"><span class="glyph">●</span>Surveillance, detection, and containment. (See <a class="local">'Surveillance and detection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Confirmation and case detection. (See <a class="local">'Confirmation and diagnostic testing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Directed prophylaxis as required for possible exposure. (See <a class="local">'Indications'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Directed therapy as required for possible or confirmed disease </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clean up and/or epidemiological investigation as necessary</p><p></p><p class="headingAnchor" id="H16715254"><span class="h1">SURVEILLANCE AND DETECTION</span><span class="headingEndMark"> — </span>Effective surveillance systems for detection of biological outbreaks need to include real time data from emergency rooms, laboratories, pharmacies and even schools to identify patterns of illness. These early responses are important for timely distribution of prophylactic medications or vaccines. The Centers for Disease Control and Prevention (CDC) can often deploy a specialized epidemiological and laboratory response team to assist in the investigations of unexplained or suspicious outbreaks at the request of state health departments, or if federally mandated.</p><p class="headingAnchor" id="H971560334"><span class="h2">The role of the clinician</span><span class="headingEndMark"> — </span>Primary health care providers, emergency department physicians, intensivists, infection control practitioners, and infectious disease physicians may be the first persons to recognize disease caused by a variety of biological agents, including pathogens that are infrequently seen. Clinicians must remain mindful that an outbreak of disease might be the result of an intentional exposure [<a href="#rid16">16</a>]. Bioterrorism may be suspected when unusually high rates of a single illness are seen, or an unusual pathogen is isolated in the laboratory. </p><p>In general, the specific presentation can suggest certain pathogens. For example, skin lesions could be caused by anthrax, smallpox, or tularemia. Swollen lymph nodes could suggest bubonic plague; paralysis could suggest botulism. Undifferentiated febrile illness could be consistent with many agents. </p><p class="headingAnchor" id="H20472973"><span class="h2">Organisms of concern</span><span class="headingEndMark"> — </span>The CDC has identified a number of pathogens that could be used in biological terrorism and have ranked them into various categories based on their overall potential to cause harm (<a class="graphic graphic_table graphicRef79744" href="/d/graphic/79744.html" rel="external">table 1</a>) [<a href="#rid17">17-19</a>]. High-priority agents include organisms that can be easily disseminated or transmitted person-to-person, cause high mortality, might cause public panic and social disruption, and require special action for public health preparedness.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Category A agents</strong> are the highest priority. These agents are of particular concern because they can be grown easily in large quantities and are sturdy organisms, resistant to destruction. They are also particularly well suited to airborne dissemination, thereby infecting large numbers of people. Examples include (<a class="graphic graphic_table graphicRef79744" href="/d/graphic/79744.html" rel="external">table 1</a>): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>Bacillus anthracis</em> (anthrax) (see  <a class="medical medical_review" href="/d/html/5533.html" rel="external">"Clinical manifestations and diagnosis of anthrax"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Variola virus (smallpox) (see  <a class="medical medical_review" href="/d/html/8341.html" rel="external">"Variola virus (smallpox)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Category B agents</strong> are the second highest priority. They are moderately easy to spread, and generally cause less morbidity and mortality than Category A but may require enhanced diagnostic capacity or surveillance techniques. Examples include (<a class="graphic graphic_table graphicRef79744" href="/d/graphic/79744.html" rel="external">table 1</a>): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>Coxiella burnetii </em>(Q fever) </p><p class="bulletIndent2"><span class="glyph">•</span><em>Brucella</em> spp (brucellosis) (see  <a class="medical medical_review" href="/d/html/3140.html" rel="external">"Brucellosis: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Category C agents</strong> include pathogens that could be engineered for mass dissemination either because of ready availability, or ease of production and transport. They are usually agents of significant potential morbidity and/or mortality. Examples include (<a class="graphic graphic_table graphicRef79744" href="/d/graphic/79744.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hantavirus (see  <a class="medical medical_review" href="/d/html/8321.html" rel="external">"Hantavirus cardiopulmonary syndrome"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Multidrug-resistant <em>Mycobacterium tuberculosis</em> (See  <a class="medical medical_review" href="/d/html/7026.html" rel="external">"Pulmonary tuberculosis: Clinical manifestations and complications"</a>.)</p><p></p><p class="headingAnchor" id="H5382341"><span class="h2">Toxins of concern</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ricin</strong>, listed as a Category B agent, is a toxin naturally found in castor beans. The clinical manifestations of ricin poisoning differ by route of exposure. Inhalational ricin may cause respiratory distress, fever, cough and pulmonary edema. Effects of this toxin may occur within eight hours of inhalation. Ingestion of ricin can lead to symptoms of vomiting, bloody diarrhea and dehydration within six hours. In severe cases, multi-organ failure can occur. </p><p></p><p class="bulletIndent1">There is no commercially available antidote; in addition to supportive care, gastric lavage and activated charcoal may be useful in some cases. Decontamination procedures should be undertaken for skin or clothing contamination since ricin can also cause burns. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trichothecene mycotoxins</strong>, derived from fungi, have also been used in aerosolized or powdered formulations for bioterrorism. These mycotoxins can lead to minor symptoms such as contact pruritus, burning, or blistering to severe symptoms such as vomiting and ataxia with hypotension and coagulopathy. Inhalation or ingestion are more likely to cause systemic effects than cutaneous exposures. No vaccine or chemoprophylactic agents exist.</p><p></p><p>If ricin or mycotoxin exposure is suspected, the CDC should be contacted for assistance, including diagnosis. </p><p class="headingAnchor" id="H1500621998"><span class="h1">PUBLIC HEALTH NOTIFICATION</span><span class="headingEndMark"> — </span>In the event of a possible terrorist event, local emergency response systems should be activated by dialing 911 in the United States, or equivalent emergency telephone numbers in other countries. In communities without 911 systems, local law enforcement officials should be notified. The local FBI office and local and state public health authorities should also be notified, who in turn will notify other federal agencies if appropriate.</p><p>A number of prominent academic centers in the United States have created Preparedness and Emergency Response Research Centers (PERRCs) [<a href="#rid20">20</a>]. These centers act as coordinating points to improve cooperation between public health and emergency medical systems.</p><p>The public health response to bioterrorism also requires effective communication and coordination with first responders and law enforcement officials. Public messaging through the general media can alert the wider community. Collaboration between the media and public health agencies has occurred during prior major outbreaks in the United States (ie, anthrax and pandemic influenza).</p><p class="headingAnchor" id="H16715268"><span class="h1">CONFIRMATION AND DIAGNOSTIC TESTING</span><span class="headingEndMark"> — </span>Once a potential bioterrorist event has been suspected or detected, the etiologic agent must be confirmed.</p><p>Appropriate collection of clinical specimens is crucial to detection:</p><p class="bulletIndent1"><span class="glyph">●</span>Post-exposure specimens should be collected within the first 24 hours. Clinical specimens typically include a nasal swab or sputum. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For asymptomatic individuals known or presumed to be exposed in a bioterrorism event based on epidemiology, prophylaxis (if available) should be offered immediately and regardless of results of post-exposure testing.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Symptomatic individuals known or presumed to be exposed generally warrant more extensive testing. In general, for symptomatic patients, especially with pulmonary symptoms, lower respiratory tract sputum (induced if necessary) is the optimal specimen. Culture and polymerase chain reaction (PCR) testing are usually performed. If a clinical syndrome defies diagnosis, additional testing using serology and possibly molecular testing (ie, next-generation sequencing) may be required to make a diagnosis. Refer to other topic reviews of potential etiologic agents for discussion of diagnosis. </p><p></p><p>As part of the national preparedness effort, a network of laboratories that communicate directly with the public health infrastructure has been developed [<a href="#rid21">21</a>]. Similar moves in the European Union plan to link all major biosafety laboratories together to enable a more effective response [<a href="#rid22">22</a>]. Every state public health laboratory in the United States now has the ability to respond to a biological terrorism emergency, either individually or through the regional or federal support system.</p><p class="headingAnchor" id="H16715275"><span class="h1">DECONTAMINATION (OVERT EXPOSURE)</span><span class="headingEndMark"> — </span>The extent of decontamination required in the event of a biological event depends on the degree of spread in an affected area, the number of individuals affected, and most critically, the organism of concern. Public health experts, emergency responders, and possibly criminal experts guide this response.</p><p class="headingAnchor" id="H1212302"><span class="h2">Personal decontamination</span><span class="headingEndMark"> — </span>If personal decontamination is required, the Centers for Disease Control and Prevention (CDC) guidelines recommend that all clothing and personal effects be removed and placed in plastic bags. Persons should be instructed to shower using copious quantities of soap and water. Plastic bags with personal effects should be labeled clearly with the owner's name, contact telephone number, and inventory of the bag's contents. Personal items may be kept as evidence in a criminal trial or returned to the owner if the threat is unsubstantiated.</p><p>Careful hand cleansing is important; one study evaluated different agents that might be used for hand washing after contact with anthrax [<a href="#rid23">23</a>]. Regular soap and water were as effective in the removal of spores similar to anthrax as antimicrobial soap or 2 percent <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> gluconate. However, an ethyl alcohol waterless rub was <strong>not</strong> active against these spores and is not recommended [<a href="#rid23">23,24</a>]. (See  <a class="medical medical_review" href="/d/html/5535.html" rel="external">"Prevention of anthrax", section on 'Infection control'</a>.)</p><p class="headingAnchor" id="H1212309"><span class="h2">Environmental decontamination</span><span class="headingEndMark"> — </span>Environmental surfaces should be cleaned thoroughly after a suspected exposure once the crime scene investigation is complete. Surfaces may be decontaminated with a 0.5 percent <a class="drug drug_general" data-topicid="9933" href="/d/drug information/9933.html" rel="external">sodium hypochlorite solution</a> (ie, one part household bleach to 10 parts water) [<a href="#rid25">25</a>]. Personal effects may be decontaminated similarly. </p><p>Although sodium hypochlorite is a safe and effective decontaminating agent for environmental surfaces and equipment, it is not recommended for human skin [<a href="#rid24">24</a>]. </p><p class="headingAnchor" id="H945812443"><span class="h1">PROPHYLAXIS</span></p><p class="headingAnchor" id="H1212400"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Determination of who should receive prophylaxis will depend on the suspected agent of concern and the associated route of transmission. As an example, the definition of a "close contact" depends on whether the suspected agent is acquired through inhalation versus contact. </p><p class="headingAnchor" id="H1212415"><span class="h2">Selection of prophylaxis type</span><span class="headingEndMark"> — </span>The type of prophylaxis will depend on the agent or toxin that is suspected. </p><p>State and regional public health officials guide clinicians as to the suspected pathogen and preferred prophylaxis to use depending on local supplies. The Department of Health and Human Services houses the Strategic National Stockpile (SNS) for rapid response to such large-scale events with supplies to where they are most needed [<a href="#rid26">26</a>]. </p><p class="headingAnchor" id="H1212574"><span class="h3">Chemoprophylaxis</span><span class="headingEndMark"> — </span>Chemoprophylaxis is available for many infections, such as the etiologic agents of anthrax, plague, tularemia, brucellosis and Q fever. <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">Ciprofloxacin</a> and <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> are used for the agents of anthrax, tularemia, and plague [<a href="#rid27">27</a>]. <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> may have a role in chemoprophylaxis for glanders and melioidosis [<a href="#rid28">28</a>]. For brucellosis, combination therapy with doxycycline and <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> for 21 days is preferred [<a href="#rid29">29</a>]. The chemoprophylaxis of children or pregnant women requires a careful risk-benefit assessment, given the potential problems with antibiotics in special populations. (See  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones"</a> and  <a class="medical medical_review" href="/d/html/494.html" rel="external">"Tetracyclines"</a>.)</p><p>For anthrax, monoclonal antibodies can also be used for post-exposure prophylaxis when no other options are available, as below.</p><p class="headingAnchor" id="H1212665"><span class="h3">Antitoxins</span><span class="headingEndMark"> — </span>A number of antitoxins have been developed to counteract the effect of biologic agents. To date, these have been designed to protect against ricin, botulism and anthrax, although only some have progressed to commercial availability at this point [<a href="#rid30">30</a>]. Two monoclonal antibodies that neutralize Bacillus anthracis toxin, <a class="drug drug_general" data-topicid="87468" href="/d/drug information/87468.html" rel="external">raxibacumab</a> and <a class="drug drug_general" data-topicid="107447" href="/d/drug information/107447.html" rel="external">obiltoxaximab</a>, are approved by the US Food and Drug Administration for the prevention and treatment of inhalational anthrax [<a href="#rid31">31,32</a>]. A polyclonal anthrax antibody is approved for the treatment of anthrax [<a href="#rid33">33</a>]. A supply of these products is held in the SNS in the event of an anthrax emergency. The use of these therapies is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/15309.html" rel="external">"Treatment of anthrax", section on 'Antitoxins'</a> and  <a class="medical medical_review" href="/d/html/5535.html" rel="external">"Prevention of anthrax", section on 'Monoclonal antibodies'</a>.)</p><p class="headingAnchor" id="H487680162"><span class="h3">Immunization</span><span class="headingEndMark"> — </span>Although the principle of immunization to prevent disease has been shown to be effective in some large-scale outbreaks (eg, H1N1 influenza vaccine, SARS-CoV-2 vaccine), the value of mass vaccination after a biological event is unclear. </p><p>In cases of suspected or documented bioterrorism, vaccines are available for the prevention of anthrax [<a href="#rid34">34</a>], smallpox, Ebola, and cholera. Other vaccines are only available through special dispensation from the CDC (eg, vaccines effective against the causative agents of Q fever, the various viral encephalitides). Some vaccines, such as those directed against Ebola, anthrax, and smallpox, are stockpiled.</p><p class="headingAnchor" id="H16715289"><span class="h1">INFECTION CONTROL</span><span class="headingEndMark"> — </span>The Centers for Disease Control and Prevention (CDC), in conjunction with the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Disease Society of America (IDSA) produced guidelines designed to assist in the care of hospitalized patients and outpatients regardless of their diagnosis or presumed infectious status [<a href="#rid35">35</a>]. </p><p>Required precautions are disease specific; the types of precautions that are instituted will depend on the suspected or documented pathogen as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Airborne precautions (eg, smallpox, hemorrhagic fevers, tuberculosis, measles, SARS-CoV-2)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Droplet precautions (eg, plague, influenza; although these are the precautions used for natural infection, in a biological weapons scenario, enhanced transmission may be a risk, and a lower threshold to use airborne precautions for nonairborne pathogens is warranted)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Contact precautions (eg, salmonella)</p><p></p><p>Secondary person-to-person transmission is possible with a number of biologic agents, especially smallpox, pneumonic plague, and the agents of hemorrhagic fever, so attention to hospital-acquired or community-based transmission is needed [<a href="#rid36">36</a>]. Samples from toxin-exposed subjects can be dealt with routinely. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection"</a>.)</p><p class="headingAnchor" id="H16715296"><span class="h1">PSYCHOLOGICAL CONSIDERATIONS</span><span class="headingEndMark"> — </span>One consequence of a terrorist attack is the residual psychological impact on the affected patients and the surrounding community. This will include overload of medical facilities by the "worried well" and grief responses by the survivors. Furthermore, past experience with the severe acute respiratory syndrome (SARS) suggested that some people who were ill delayed seeking care, because they perceived medical centers as being the source of the contagion [<a href="#rid37">37</a>].</p><p>Psychological morbidity for first-responders, medical personnel, and the public can be significant in the event of a terrorist event, so clinicians should be mindful of depression, pathologic bereavement, acute stress disorder (ASD) and post-traumatic stress disorder (PTSD) [<a href="#rid16">16,38</a>].</p><p class="headingAnchor" id="H16715303"><span class="h1">EMERGENCY RESOURCES</span></p><p>Centers for Disease Control and Prevention (CDC) – Division of Emergency Preparedness and Response</p><p><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.emergency.cdc.gov%2F&amp;token=NyRkA1K%2BEfcjom0B%2Bqruks%2Bvh%2FP9S5sx0%2F1pp7TVd3GyT%2BfGLWmSDQ1t%2B%2BTYBX1o&amp;TOPIC_ID=2735" target="_blank">www.emergency.cdc.gov/</a></p><p>CDC Emergency Response Coordinating Group:</p><p>770-488-7100 (health professionals or government officials only)</p><p>Regional Poison Control Centers:</p><p>1-800-222-1222</p><p>CDC Coordinating Office for Terrorism Preparedness and Emergency Response:</p><p>404-639-7405</p><p>CDC Division of Bioterrorism Preparedness and Response:</p><p>404-639-0385</p><p>Federal Bureau of Investigation (FBI): </p><p>1-855-835-5324</p><p class="headingAnchor" id="H1666981705"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109936.html" rel="external">"Society guideline links: Anthrax"</a>.)</p><p class="headingAnchor" id="H5182875"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Detection of biological agents can be difficult since biological events are frequently invisible and lead to slow accumulation of casualties, in contrast to chemical spills, which often lead to rapid casualties. (See <a class="local">'Overview of detection and response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An astute clinician may be the first to recognize either a large outbreak of one disease or an unusual pathogen, which may be the first sign of biological terrorism. (See <a class="local">'The role of the clinician'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Effective surveillance systems for detection of biological outbreaks need to include real time data from emergency rooms, laboratories, pharmacies and even schools to identify patterns of illness. These early responses are important for timely distribution of prophylactic medications or vaccines. (See <a class="local">'Surveillance and detection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Centers for Disease Control and Prevention (CDC) has identified a number of pathogens that could be used in biological terrorism and have ranked them into various categories based on their overall potential to cause harm. The pathogens of greatest concern include anthrax and smallpox (<a class="graphic graphic_table graphicRef79744" href="/d/graphic/79744.html" rel="external">table 1</a>). (See <a class="local">'Organisms of concern'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the event of a possible terrorist event, local emergency responses systems should be activated by dialing 911 in the United States, or equivalent emergency telephone numbers in other countries. (See <a class="local">'Public health notification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Post-exposure specimens should be collected within the first 24 hours and prophylaxis should be offered (if available). Most clinical specimens include a nasal swab or sputum; culture and polymerase chain reaction (PCR) testing are usually performed. (See <a class="local">'Confirmation and diagnostic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In overt exposures, both personal and environmental decontamination may be required. (See <a class="local">'Decontamination (overt exposure)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>State and regional public health officials will guide clinicians as to the suspected pathogen and preferred prophylaxis to use depending on local supplies. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The type of prophylaxis will depend on the agent or toxin that is suspected; possibilities include chemoprophylaxis (eg, antibiotics), immunizations, or antitoxins. (See <a class="local">'Prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Airborne, droplet or contact precautions will be established depending on the agent of concern. (See <a class="local">'Infection control'</a> above.)</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff acknowledges Cameron Wolfe, MBBS (Hons), who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Eitzen E, Takafuji E. Textbook of Military Medicine, Chapter 18 Historical Overview of Biological Warfare – page 417; Office of the Surgeon General, Department of the Army, United States of America. http://www.bvsde.ops-oms.org/tutorial1/fulltex/armas/textos/chebio/chebio.pdf#page=424 (Accessed on January 11, 2013).</li><li class="breakAll">Office of Technology Assessment, US Congress. Proliferation of Weapons of Mass Destruction. Washington, DC: US Government Printing Office; 1993:53-55. Publication OTA-ISC-559.</li><li class="breakAll">Vogel, KM.. Phantom Menace or Looming Danger?: A New Framework for Assessing Bioweapons Threats, The Johns Hopkins University Press, Baltimore 2013.</li><li><a class="nounderline abstract_t">Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM Jr. Biological warfare. A historical perspective. JAMA 1997; 278:412.</a></li><li><a class="nounderline abstract_t">Davis CJ. Nuclear blindness: An overview of the biological weapons programs of the former Soviet Union and Iraq. Emerg Infect Dis 1999; 5:509.</a></li><li class="breakAll">Kortepeter M, Christopher GW, Cieslak T, et al (Eds). Medical Management of Biological Casualties, 4th ed. USAMRIID, Ft Detrick, Frederick, Maryland, February 2001.</li><li><a class="nounderline abstract_t">Zilinskas RA. Iraq's biological weapons. The past as future? JAMA 1997; 278:418.</a></li><li><a class="nounderline abstract_t">Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266:1202.</a></li><li><a class="nounderline abstract_t">Török TJ, Tauxe RV, Wise RP, et al. A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars. JAMA 1997; 278:389.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Update: Investigation of bioterrorism-related anthrax--Connecticut, 2001. MMWR Morb Mortal Wkly Rep 2001; 50:1077.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Investigation of a ricin-containing envelope at a postal facility--South Carolina, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:1129.</a></li><li class="breakAll">CNN Politics. FBI confirms letters to Obama, others contained ricin. http://www.cnn.com/2013/04/18/politics/tainted-letter-intercepted/ (Accessed on August 18, 2016).</li><li><a class="nounderline abstract_t">Dalton R. Biosafety lab passes disaster test. Nature 2008; 455:1012.</a></li><li><a class="nounderline abstract_t">Okumura T, Takasu N, Ishimatsu S, et al. Report on 640 victims of the Tokyo subway sarin attack. Ann Emerg Med 1996; 28:129.</a></li><li class="breakAll">Carus, WS. Bioterrorism and Biocrimes: The Illicit Use of Biological Agents Since 1900, Reprint of First Edition, Fredonia Books, Amsterdam 2002. p.63-65.</li><li><a class="nounderline abstract_t">Chung S, Baum CR, Nyquist AC, DISASTER PREPAREDNESS ADVISORY COUNCIL, COUNCIL ON ENVIRONMENTAL HEALTH, COMMITTEE ON INFECTIOUS DISEASES. Chemical-Biological Terrorism and Its Impact on Children. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Biological and chemical terrorism: strategic plan for preparedness and response. Recommendations of the CDC Strategic Planning Workgroup. MMWR Recomm Rep 2000; 49:1.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Bioterrorism Agents/Diseases, by Category http://emergency.cdc.gov/agent/agentlist-category.asp (Accessed on September 21, 2012).</li><li><a class="nounderline abstract_t">Adalja AA, Toner E, Inglesby TV. Clinical management of potential bioterrorism-related conditions. N Engl J Med 2015; 372:954.</a></li><li class="breakAll">CDC Division of Media Relations, CDC awards $2.7 million for two new Preparedness Research Centers; Jan 7, 2010 http://www.cdc.gov/media/pressrel/2010/r100107.htm (Accessed on January 11, 2013).</li><li class="breakAll">Centers for Disease Control and Prevention. Emergency Preparedness and Response: The Laboratory Response Network Partners in Preparedness. https://emergency.cdc.gov/lrn/index.asp (Accessed on November 18, 2021).</li><li><a class="nounderline abstract_t">Butler D. European biosafety labs set to grow. Nature 2009; 462:146.</a></li><li><a class="nounderline abstract_t">Weber DJ, Sickbert-Bennett E, Gergen MF, Rutala WA. Efficacy of selected hand hygiene agents used to remove Bacillus atrophaeus (a surrogate of Bacillus anthracis) from contaminated hands. JAMA 2003; 289:1274.</a></li><li><a class="nounderline abstract_t">Rutala WA, Weber DJ. Uses of inorganic hypochlorite (bleach) in health-care facilities. Clin Microbiol Rev 1997; 10:597.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Bioterrorism alleging use of anthrax and interim guidelines for management--United States, 1998. MMWR Morb Mortal Wkly Rep 1999; 48:69.</a></li><li class="breakAll">United States Department of Health and Human Services. Strategic National Stockpile. https://www.phe.gov/about/sns/Pages/default.aspx (Accessed on November 18, 2021).</li><li><a class="nounderline abstract_t">Russell P, Eley SM, Bell DL, et al. Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice. J Antimicrob Chemother 1996; 37:769.</a></li><li><a class="nounderline abstract_t">Russell P, Eley SM, Ellis J, et al. Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. J Antimicrob Chemother 2000; 45:813.</a></li><li><a class="nounderline abstract_t">Robichaud S, Libman M, Behr M, Rubin E. Prevention of laboratory-acquired brucellosis. Clin Infect Dis 2004; 38:e119.</a></li><li><a class="nounderline abstract_t">Rainey GJ, Young JA. Antitoxins: novel strategies to target agents of bioterrorism. Nat Rev Microbiol 2004; 2:721.</a></li><li class="breakAll">FDA approves raxibacumab to treat inhalational anthrax, Dec. 14, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332341.htm (Accessed on January 11, 2013).</li><li class="breakAll">US Food and Drug Administration. FDA approves new treatment for inhalation anthrax. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm491470.htm (Accessed on August 18, 2016).</li><li class="breakAll">US Food and Drug Administration. FDA approves treatment for inhalation anthrax. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm439752.htm (Accessed on August 18, 2016).</li><li><a class="nounderline abstract_t">Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996; 17:53.</a></li><li><a class="nounderline abstract_t">Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control 2007; 35:S65.</a></li><li><a class="nounderline abstract_t">Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2000; 283:2281.</a></li><li><a class="nounderline abstract_t">Rubin GJ, Dickmann P. How to reduce the impact of "low-risk patients" following a bioterrorist incident: lessons from SARS, anthrax, and pneumonic plague. Biosecur Bioterror 2010; 8:37.</a></li><li><a class="nounderline abstract_t">Smith CG, Veenhuis PE, MacCormack JN. Bioterrorism. A new threat with psychological and social sequelae. N C Med J 2000; 61:150.</a></li></ol></div><div id="topicVersionRevision">Topic 2735 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.bvsde.ops-oms.org/tutorial1/fulltex/armas/textos/chebio/chebio.pdf#page=424" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Eitzen E, Takafuji E. Textbook of Military Medicine, Chapter 18 Historical Overview of Biological Warfare – page 417; Office of the Surgeon General, Department of the Army, United States of America. http://www.bvsde.ops-oms.org/tutorial1/fulltex/armas/textos/chebio/chebio.pdf#page=424 (Accessed on January 11, 2013).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Office of Technology Assessment, US Congress. Proliferation of Weapons of Mass Destruction. Washington, DC: US Government Printing Office; 1993:53-55. Publication OTA-ISC-559.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Vogel, KM.. Phantom Menace or Looming Danger?: A New Framework for Assessing Bioweapons Threats, The Johns Hopkins University Press, Baltimore 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9244333" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Biological warfare. A historical perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10458954" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Nuclear blindness: An overview of the biological weapons programs of the former Soviet Union and Iraq.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10458954" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Nuclear blindness: An overview of the biological weapons programs of the former Soviet Union and Iraq.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9244334" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Iraq's biological weapons. The past as future?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7973702" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The Sverdlovsk anthrax outbreak of 1979.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9244330" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11770501" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Update: Investigation of bioterrorism-related anthrax--Connecticut, 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14627953" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Investigation of a ricin-containing envelope at a postal facility--South Carolina, 2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14627953" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Investigation of a ricin-containing envelope at a postal facility--South Carolina, 2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18948912" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Biosafety lab passes disaster test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8759575" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Report on 640 victims of the Tokyo subway sarin attack.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8759575" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Report on 640 victims of the Tokyo subway sarin attack.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31988168" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chemical-Biological Terrorism and Its Impact on Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10803503" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Biological and chemical terrorism: strategic plan for preparedness and response. Recommendations of the CDC Strategic Planning Workgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10803503" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Biological and chemical terrorism: strategic plan for preparedness and response. Recommendations of the CDC Strategic Planning Workgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25738671" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical management of potential bioterrorism-related conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25738671" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical management of potential bioterrorism-related conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25738671" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical management of potential bioterrorism-related conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19907462" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : European biosafety labs set to grow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12633189" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Efficacy of selected hand hygiene agents used to remove Bacillus atrophaeus (a surrogate of Bacillus anthracis) from contaminated hands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9336664" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Uses of inorganic hypochlorite (bleach) in health-care facilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10023627" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Bioterrorism alleging use of anthrax and interim guidelines for management--United States, 1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10023627" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bioterrorism alleging use of anthrax and interim guidelines for management--United States, 1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8722542" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10837435" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15227634" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prevention of laboratory-acquired brucellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15372082" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Antitoxins: novel strategies to target agents of bioterrorism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15372082" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Antitoxins: novel strategies to target agents of bioterrorism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15372082" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antitoxins: novel strategies to target agents of bioterrorism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15372082" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Antitoxins: novel strategies to target agents of bioterrorism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8789689" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18068815" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10807389" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20230231" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : How to reduce the impact of "low-risk patients" following a bioterrorist incident: lessons from SARS, anthrax, and pneumonic plague.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10832374" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Bioterrorism. A new threat with psychological and social sequelae.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
